FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2184-2185 May 15, 2008 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hunter, D. J. PubMed Citation

To the Editor: The Perspective article by Hunter et al. (Jan. 10 issue)¹ concludes that commercialization of personal genomics is premature in light of the lack of data to support the analytic and clinical validity and clinical utility of these tests. Although the authors' description of the current state of the art is accurate, they and others² minimize the important point that clinical practice has already been influenced by the possibility of personal genomics, and it is consumers' attitudes — not outcomes data — that are the critical drivers of such changes.

Despite what most geneticists and physicians would view . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.